New Developments in Breast Cancer Therapy Presented at ASCO 2010

[摘要] Dubsky: Endocrine treatment: One of the highlights was the contribution by the Austrian Breast and Colorectal Cancer Study Group (ABCSG) concerning the impact of BMI on endocrine treatment (Disclosure: I am a co-author). The study investigated the impact of BMI in premenopausal patients undergoing endocrine treatment with goserelin combined either with tamoxifen or anastrozole (retrospective analysis of patients from ABCSG-12). Overweight patients treated with anastrozole double their risk of death. No such impact of BMI is seen in tamoxifen treated patients. It is noteworthy that these results were confirmed in a retrospective analysis of the ATAC trial published shortly after the ASCO meeting (Sestak et al.; J Clin Oncol 2010;28:3411–5.).

[学科分类] 泌尿医学